Skip to main content
Ovoca Bio Plc logo

Ovoca Bio Plc — Investor Relations & Filings

Ticker · OVXA ISIN · IE00B4XVDC01 LEI · 213800ST2AK5XQ1O5207 IR Manufacturing
Open in API
Filings indexed 99 across all filing types
Latest filing 2023-03-16 Regulatory Filings
Country IE Ireland
Listing IR OVXA

About Ovoca Bio Plc

https://ovocabio.com/

Ovoca Bio is a clinical-stage biopharmaceutical company focused on developing novel treatments for women's health. Its lead product candidate is Orenetide, a treatment for premenopausal women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack of sexual desire and representing a significant area of high unmet medical need. The company is advancing Orenetide through clinical development for major global markets and has filed for marketing approval in the US and Europe. Ovoca Bio's strategy includes leveraging its patent portfolio and considering licensing or collaboration opportunities to accelerate the availability of its product candidates to patients.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document is very short (1928 chars) and contains the header 'RNS Number : 2593T'. It discusses a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, or MANG), the most appropriate classification is the general regulatory filing fallback category.
2023-03-16 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1911 characters) and contains the header 'RNS Number : 2579T'. It announces a 'Price Monitoring Extension' related to trading procedures on the London Stock Exchange. It explicitly states that the information is provided by RNS, the news service of the London Stock Exchange, and is approved by the Financial Conduct Authority (FCA). This structure—a brief, specific operational announcement distributed via the RNS system—fits best under the general Regulatory Filings category, as it is not a core financial report (like 10-K, IR, ER) nor does it fit the specific definitions for DIRS, DIV, or MANG. It is a regulatory notification.
2023-03-16 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1928 characters) and contains the header 'RNS Number : 2092T' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Second Price Monitoring Extension' for a security, which is a specific, immediate operational announcement related to trading halts or extensions. This type of brief, time-sensitive regulatory update that doesn't fit into standard financial reporting categories (like 10-K, ER, IR) is best classified as a general Regulatory Filing (RNS), as it is explicitly distributed via the RNS system.
2023-03-16 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1911 characters) and announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange. It explicitly mentions 'RNS Number' and is distributed by 'RNS, the news service of the London Stock Exchange,' which is approved by the Financial Conduct Authority (FCA) as a Primary Information Provider. This structure strongly indicates a general regulatory announcement that does not fit into the specific categories like 10-K, ER, or DIV. Therefore, it falls under the general Regulatory Filings category.
2023-03-16 English
Disposal of Russian Assets
Environmental & Social Information Classification · 99% confidence The document begins with 'RNS Number : 1981S' and contains standard regulatory boilerplate language at the end, including references to 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. The content announces a specific corporate action: the 'Disposal of Russian Assets' for cash consideration. This type of material announcement, which is not a full financial report (like 10-K or IR) but a significant corporate event disclosure distributed via the regulatory news service, fits best under the general 'Regulatory Filings' category (RNS) as it is a broad announcement disseminated through the official channel, rather than a specific filing type like Director's Dealing (DIRS) or Capital Change (CAP). Since it is a formal announcement distributed via RNS, RNS is the most appropriate classification.
2023-03-08 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1931 characters) and contains the header 'RNS Number : 9198P'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates a general regulatory announcement that does not fit into the specific financial reporting categories (like 10-K, ER, IR). Therefore, the most appropriate classification is the general Regulatory Filings category (RNS).
2023-02-14 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.